The 2-Minute Rule for ABBV-744 in the treatment of drug-resistant cancers
In Section C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Individuals will get treatment until disorder progression or perhaps the contributors are not able to tolerate the study drugs.There might be increased treatment load for participants With this trial when compared with